Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
26 feb 2009 - 20:02
Statutaire naam
Crucell N.V.
Titel
Crucell's Revolutionary Antibody for Universal Therapy Against Flu
Bericht
Leiden, The Netherlands (February 26, 2009) – Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) announces that the journal Science today published a study showing why Crucell's novel anti-influenza antibody is so effective against such a broad range of influenza virus subtypes. These characteristics make the Crucell antibody CR6261 a potentially revolutionary therapy against seasonal and pandemic flu.
“A new therapy for the often deadly flu virus is much needed”, says Jaap Goudsmit, CSO of Crucell. “The continuous mutation of the influenza virus means that vaccine developers are always playing catch-up when it comes to choosing the correct virus. In addition, these vaccines tend to perform less effectively in the elderly. The almost universal oseltamivir resistance of the H1N1 virus presently circulating and the reported cases of H5N1 oseltamivir-resistance illustrate the urgency for a universal therapy against flu.”
Datum laatste update: 21 februari 2026